Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger, +14

Cancer Research

Drug TargetingBreast OncologyDisulfide LinkersMedicineImmunology +10

A Central Role for HER3 in <i>HER2</i> -Amplified Breast Cancer: Implications for Targeted Therapy

Si Tuen Lee-Hoeflich, Lisa Crocker, Evelyn Yao, +5

Cancer Research

A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies

Gabriele Schaefer, Lauric Haber, Lisa Crocker, +20

Cancer Cell

Immunocytochemical TechniqueAllergyAutoimmune DiseaseImmunologyAntibody Screening +7

Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer

Uzma Asghar, Alexis R. Barr, Ros Cutts, +11

Clinical Cancer Research

Superior <i>In vivo</i> Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer

Teemu T. Junttila, Kathryn L. Parsons, Christine Olsson, +10

Cancer Research

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

Gail D. Lewis Phillips, Carter T. Fields, Guangmin Li, +14

Clinical Cancer Research

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells

Guangmin Li, Jun Guo, Ben‐Quan Shen, +5

Molecular Cancer Therapeutics

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

Nelson L. ‘Shasha’ Jumbe, Xin Yan, Douglas D. Leipold, +6

Journal of Pharmacokinetics and Pharmacodynamics

Drug TargetingAntibody Drug ConjugateMedicineImmunologyImmune Checkpoint Inhibitor +7

Blocking NRG1 and Other Ligand-Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Non–Small Cell Lung Cancer

Ganapati V. Hegde, Cecile C. de la Cruz, Cecilia Chiu, +18

Science Translational Medicine

IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment

Jonathan M. Harnoss, Adrien Le Thomas, Mike Reichelt, +18

Cancer Research